BULN
MCID: BLM002
MIFTS: 57

Bulimia Nervosa (BULN)

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Bulimia Nervosa

MalaCards integrated aliases for Bulimia Nervosa:

Name: Bulimia Nervosa 56 12 74 54 43 15 17 71 32
Bulimia Nervosa, Susceptibility to 56 13
Bulimia 43 71
Bulimia Nervosa, Susceptibility to, Type 2 39
Susceptibility to Bulimia Nervosa 29
Binge Eating Disorder 71
Hyperorexia Nervosa 12
Bulimia Nervosa 2 73
Buln2 73
Buln 56
Bn 56

Characteristics:

OMIM:

56
Inheritance:
multifactorial


HPO:

31
bulimia nervosa:
Inheritance multifactorial inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:12129
OMIM 56 607499
NCIt 49 C97162
ICD10 32 F50.2
SNOMED-CT via HPO 68 78004001
UMLS 71 C0006370 C0596170 C2267227

Summaries for Bulimia Nervosa

OMIM : 56 Bulimia nervosa (BN) is a psychiatric disorder characterized by episodes of binge-eating (eating an unusually large amount of food in a discrete period of time and feeling out of control), compensatory behavior (e.g., self-induced vomiting or laxative abuse), and over-concern with weight and shape. Eating disorders such as bulimia nervosa are complex disorders that can be influenced by many genes. (607499)

MalaCards based summary : Bulimia Nervosa, also known as bulimia nervosa, susceptibility to, is related to avoidant personality disorder and amenorrhea, and has symptoms including salt craving, decrease in appetite and symptoms. An important gene associated with Bulimia Nervosa is BULN (Bulimia Nervosa, Susceptibility To), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Dopamine and Memantine have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and cortex, and related phenotypes are bulimia and behavior/neurological

Disease Ontology : 12 An eating disorder characterized by the restraining of food intake for a period of time followed by an over intake or binging period that results in feelings of guilt and low self-esteem.

UniProtKB/Swiss-Prot : 73 Bulimia nervosa 2: A psychiatric disorder characterized by eating an unusually large amount of food in a short period of time, followed by inappropriate acts (purging) to avert weight gain. Compensatory behavior includes self-induced vomiting, laxative abuse, and excessive exercise.

Wikipedia : 74 Bulimia nervosa, also known as simply bulimia, is an eating disorder characterized by binge eating... more...

Related Diseases for Bulimia Nervosa

Diseases related to Bulimia Nervosa via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 442)
# Related Disease Score Top Affiliating Genes
1 avoidant personality disorder 31.5 SLC6A4 MAOA HTR1B DRD4
2 amenorrhea 31.1 LEP INS GHRL
3 neurotic disorder 31.0 SLC6A4 MAOA HTR2A BDNF
4 depression 30.9 SLC6A4 MAOA HTR2C HTR2A BDNF
5 alexithymia 30.8 SLC6A4 OXT DRD2 COMT
6 eating disorder 30.6 SLC6A4 PYY NPY MC4R LEPQTL1 LEP
7 dysthymic disorder 30.5 SLC6A4 MAOA HTR2A BDNF
8 obsessive-compulsive personality disorder 30.5 SLC6A4 HTR2A COMT
9 kleptomania 30.5 SLC6A4 MAOA DRD4 DRD2
10 body dysmorphic disorder 30.4 SLC6A4 OXT MAOA HTR2A
11 somatization disorder 30.4 SLC6A4 OXT HTR2A
12 separation anxiety disorder 30.4 SLC6A4 OXT DRD4
13 acute stress disorder 30.4 SLC6A4 OXT BDNF
14 celiac disease 1 30.4 PYY INS GHRL CCK
15 conduct disorder 30.4 SLC6A4 MAOA DRD4 DRD2 COMT
16 brain injury 30.3 DRD2 COMT BDNF
17 schizotypal personality disorder 30.3 DRD4 DRD2 COMT
18 gastroesophageal reflux 30.3 PYY NPY HTR2A GHRL DRD2 CCK
19 postpartum depression 30.3 SLC6A4 OXT MAOA COMT BDNF
20 anovulation 30.2 LEP INS GHRL DRD2
21 agoraphobia 30.2 SLC6A4 MAOA HTR2A COMT BDNF
22 phobia, specific 30.2 SLC6A4 OXT MAOA COMT
23 atypical depressive disorder 30.1 SLC6A4 MAOA LEP HTR2A BDNF
24 conversion disorder 30.1 HTR2A COMT
25 hyperglycemia 30.0 PYY LEP INS GHRL CCK
26 cholelithiasis 30.0 LEP INS CCK
27 choreatic disease 30.0 DRD4 DRD2 BDNF
28 substance dependence 30.0 SLC6A4 MAOA HTR1B DRD4 DRD2 COMT
29 drug dependence 30.0 SLC6A4 NPY HTR3A DRD2 BDNF
30 melancholia 29.9 SLC6A4 MAOA HTR2A BDNF
31 autonomic neuropathy 29.9 NPY INS CCK
32 pica disease 29.9 LEP INS
33 diarrhea 29.9 SLC6A4 PYY LEP HTR3A CCK
34 pathological gambling 29.9 SLC6A4 MAOA HTR2A DRD4 DRD2 COMT
35 hyperthyroidism 29.8 LEP INS GHRL
36 cyclothymic disorder 29.8 HTR2A DRD4 DRD2 COMT
37 impulse control disorder 29.7 SLC6A4 MAOA HTR2A DRD4 DRD2 COMT
38 delusional disorder 29.6 HTR2C HTR2A DRD4 DRD2
39 nutritional deficiency disease 29.6 NPY LEPQTL1 LEP GHRL CCK BDNF
40 antisocial personality disorder 29.6 SLC6A4 MAOA HTR2A HTR1B DRD4 DRD2
41 substance abuse 29.5 SLC6A4 NPY MAOA INS HTR2A HTR1B
42 agnosia 29.5 OXT HTR3A CCK BDNF
43 post-traumatic stress disorder 29.4 SLC6A4 NPY MAOA HTR2A DRD2 COMT
44 borderline personality disorder 29.4 SLC6A4 MAOA HTR3A HTR2C HTR2A HTR1B
45 tobacco addiction 29.4 SLC6A4 MAOA HTR2A DRD4 DRD2 COMT
46 alcohol use disorder 29.4 SLC6A4 HTR3A HTR2C HTR2A HTR1B DRD2
47 constipation 29.4 SLC6A4 PYY NPY INS HTR3A HTR2A
48 glucose intolerance 29.3 NPY LEPQTL1 LEP INS GHRL
49 phobic disorder 29.3 SLC6A4 OXT MAOA HTR2A DRD2 COMT
50 social phobia 29.3 SLC6A4 OXT MAOA HTR3A DRD2 COMT

Graphical network of the top 20 diseases related to Bulimia Nervosa:



Diseases related to Bulimia Nervosa

Symptoms & Phenotypes for Bulimia Nervosa

Human phenotypes related to Bulimia Nervosa:

31
# Description HPO Frequency HPO Source Accession
1 bulimia 31 HP:0100739

Symptoms via clinical synopsis from OMIM:

56
Neurologic Behavioral Psychiatric Manifestations:
recurrent episodes of binge eating
recurrent inappropriate conpensatory behavior to prevent weight gain, including self-induced vomiting, laxative or diuretic abuse, fasting, excessive exercise
overconcern with weight and body shape
feelings of guilt associated with episodes

Clinical features from OMIM:

607499

UMLS symptoms related to Bulimia Nervosa:


salt craving, decrease in appetite, symptoms

MGI Mouse Phenotypes related to Bulimia Nervosa:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.39 BDNF COMT DRD2 DRD4 GHRL HTR1B
2 homeostasis/metabolism MP:0005376 10.22 BDNF CCK COMT DRD2 DRD4 GHRL
3 adipose tissue MP:0005375 10.18 DRD2 GHRL HTR1B HTR2C INS LEP
4 endocrine/exocrine gland MP:0005379 10.18 BDNF CCK COMT DRD2 GHRL HTR1B
5 growth/size/body region MP:0005378 10.15 BDNF DRD2 HTR1B HTR2C HTR3A INS
6 digestive/alimentary MP:0005381 10.09 BDNF DRD2 GHRL HTR2A INS LEP
7 nervous system MP:0003631 10.03 BDNF CCK COMT DRD2 DRD4 HTR2C
8 muscle MP:0005369 9.86 DRD2 HTR1B HTR2A HTR2C HTR3A INS
9 renal/urinary system MP:0005367 9.56 CCK COMT DRD2 HTR3A INS LEP
10 reproductive system MP:0005389 9.28 BDNF COMT DRD2 HTR1B HTR3A INS

Drugs & Therapeutics for Bulimia Nervosa

Drugs for Bulimia Nervosa (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 163)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
2
Memantine Approved, Investigational Phase 4 19982-08-2 4054
3
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
4
Dextroamphetamine Approved, Illicit Phase 4 51-64-9 5826
5
Amphetamine Approved, Illicit, Investigational Phase 4 300-62-9 5826 3007
6
Norepinephrine Approved Phase 4 51-41-2 439260
7
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
8
Nicotine Approved Phase 4 54-11-5 942 89594
9
Liraglutide Approved Phase 4 204656-20-2 44147092
10
Raclopride Investigational Phase 4 84225-95-6
11 Central Nervous System Stimulants Phase 4
12 Adrenergic Agents Phase 4
13 Appetite Depressants Phase 4
14 Sympathomimetics Phase 4
15 Neurotransmitter Agents Phase 4
16 Dopamine Agents Phase 4
17 Excitatory Amino Acid Antagonists Phase 4
18 Atomoxetine Hydrochloride Phase 4
19 Cytochrome P-450 Enzyme Inhibitors Phase 4
20 Antidepressive Agents Phase 4
21 Psychotropic Drugs Phase 4
22 Duloxetine Hydrochloride Phase 4
23 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
24 Analgesics Phase 4
25 Dopamine Antagonists Phase 4
26
Naloxone Approved, Vet_approved Phase 2, Phase 3 465-65-6 5284596
27
Sodium oxybate Approved Phase 2, Phase 3 502-85-2 5360545
28
Modafinil Approved, Investigational Phase 3 68693-11-8 4236
29
Acamprosate Approved, Investigational Phase 2, Phase 3 77337-76-9 71158
30
Zonisamide Approved, Investigational Phase 3 68291-97-4 5734
31
Lamotrigine Approved, Investigational Phase 3 84057-84-1 3878
32
Rimonabant Approved, Investigational Phase 3 158681-13-1, 168273-06-1 104850
33
Varenicline Approved, Investigational Phase 3 249296-44-4 5310966
34
Methadone Approved Phase 2, Phase 3 76-99-3 4095
35
Cocaine Approved, Illicit Phase 2, Phase 3 50-36-2 446220 5760
36
Naltrexone Approved, Investigational, Vet_approved Phase 2, Phase 3 16590-41-3 5360515
37
Ethanol Approved Phase 2, Phase 3 64-17-5 702
38
tannic acid Approved Phase 2, Phase 3 1401-55-4
39
Benzocaine Approved, Investigational Phase 2, Phase 3 94-09-7, 1994-09-7 2337
40
Acetylcysteine Approved, Investigational Phase 2, Phase 3 616-91-1 12035
41
Fluoxetine Approved, Vet_approved Phase 3 54910-89-3 3386
42
Phenol Approved, Experimental Phase 3 108-95-2 996
43
Glucagon Approved Phase 3 16941-32-5
44 Anesthetics, General Phase 2, Phase 3
45 Anesthetics, Intravenous Phase 2, Phase 3
46 Calcium, Dietary Phase 3
47 calcium channel blockers Phase 3
48 Tin Fluorides Phase 2, Phase 3
49 Diuretics, Potassium Sparing Phase 3
50 Sodium Channel Blockers Phase 3

Interventional clinical trials:

(show top 50) (show all 312)
# Name Status NCT ID Phase Drugs
1 An Open-Label, Prospective Trial of Memantine in the Treatment of Moderate to Severe Binge Eating Disorder Associated With Obesity Completed NCT00330655 Phase 4 memantine
2 Atomoxetine in the Treatment of Binge Eating Disorder: A Single-Center, Double-Blind, Placebo-Controlled, Flexible Dose Study in Outpatients Completed NCT00327834 Phase 4 atomoxetine
3 A 12-Week, Double-Blind, Placebo-Controlled, Trial of Duloxetine Versus Placebo in the Treatment of Binge Eating Disorder and Comorbid Depressive Disorder. Completed NCT00607789 Phase 4 Duloxetine;Placebo
4 Controlled Trial of Orlistat With Behavioral Weight Loss Therapy for Obesity and Binge Eating in Monolingual Hispanic Persons Completed NCT00516919 Phase 4 Xenical + behavioral intervention
5 Treatment of Binge Eating in Obese Patients in Primary Care Completed NCT00537810 Phase 4 Sibutramine;Placebo
6 Monoamine Contributions to Neurocircuitry in Eating Disorders Completed NCT02020408 Phase 4 [11C]raclopride;[11C]DASB;amphetamine
7 The Influence of Appetite-Related Central and Gut Hormones in Modulating Binge Eating Behaviour in Obese and Overweight Healthy Subjects Completed NCT01739049 Phase 4 Liraglutide
8 Effectiveness of Psychological Treatments for BED Completed NCT00060762 Phase 4
9 Randomized Clinical Trial Comparing a Medication, i.e., Sustained-Release Bupropion (Zyban®) With an Ultrashort (1 1/2 d) Manual-Based Psychotherapeutic Intervention, Psychodynamic Model Training® Completed NCT00484692 Phase 4 sustained-release bupropion (Zyban(R))
10 Evaluation of the Efficacy of Serotoninergic Antidepressants in Bulimia Nervosa, According to Brain Serotonin Profile Determined by Positron Emission Tomography With [18F] MPPF - a Multicenter Study Recruiting NCT02359513 Phase 4 Antidepressants;Positron Emission Tomography (PET)
11 Topiramate Augmentation in Bulimia Nervosa Partial Responders Withdrawn NCT00988481 Phase 4 Topiramate
12 Feedback Versus no Feedback to Improve Patient Outcome in Group Psychotherapy for Eating Disorders: A Randomised Clinical Trial Unknown status NCT01693237 Phase 2, Phase 3
13 The Efficacy of Readiness and Motivation Therapy in Individuals With Anorexia Nervosa and Bulimia Nervosa Unknown status NCT00220662 Phase 3
14 Clinical Controlled Trial on Extinction of Opioidergic Binge Eating Disorder (BED) With Intranasal Naloxone Administration Unknown status NCT01567670 Phase 2, Phase 3 Naloxone;naloxone placebo
15 Sodium Oxybate in the Treatment of Binge Eating Disorder Completed NCT00514995 Phase 2, Phase 3 Sodium Oxybate
16 Armodafinil in Binge Eating Disorder (BED) Completed NCT01010789 Phase 3 Armodafinil;Armodafinil;Matching placebo
17 Lisdexamfetamine in Binge Eating Disorder of Moderate or Greater Severity Completed NCT01090713 Phase 3 lisdexamfetamine;Placebo control
18 An Open-label, Flexibly-dosed, Multicenter, Extension Study of Dasotraline to Evaluate Long-term Safety and Tolerability in Adults With Binge-eating Disorder Completed NCT02684279 Phase 3 Dasotraline
19 Acamprosate in the Treatment of Binge-Eating Disorder Completed NCT00511940 Phase 2, Phase 3 acamprosate
20 Zonegran in the Treatment of Binge Eating Disorder Associated With Obesity: A Single Center, Double-Blind, Placebo-controlled, Flexible-Dose Study in Outpatients Completed NCT00221442 Phase 3 Zonegran;sugar pill
21 A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Examine the Efficacy and Safety of Meridia (Sibutramine Hydrochloride) in Binge-Eating Disorder Completed NCT00402584 Phase 3 sibutramine
22 A Phase 3, Multicenter, Open-label, 12 Month Extension Safety and Tolerability Study of SPD489 in the Treatment of Adults With Binge Eating Disorder Completed NCT01657019 Phase 3 Lisdexamfetamine dimesylate
23 A 12-week, Randomized, Double-blind, Parallel-group, Placebo Controlled, Flexibly Dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder Completed NCT02564588 Phase 2, Phase 3 Dasotraline;Placebo
24 The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder Completed NCT01718509 Phase 3 SPD489 (Lisdexamfetamine dimesylate);Placebo
25 The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder Completed NCT01718483 Phase 3 SPD489 (Lisdexamfetamine dimesylate);Placebo
26 A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder Completed NCT02009163 Phase 3 Lisdexamfetamine dimesylate
27 Randomized, Double-blind Placebo Controlled Trial With Topiramate for the Treatment of Obese Patients With Binge Eating Disorder Completed NCT00307619 Phase 3 topiramate
28 Deficits in Emotion Regulation Skills as a Maintaining Factor in Binge Eating Disorder Completed NCT03717493 Phase 2, Phase 3
29 A Multicenter, Randomized, Double-blind, Placebo-controlled, Flexible-dose Study to Assess the Safety and Efficacy of Topiramate in the Treatment of Moderate to Severe Binge-eating Disorder Associated With Obesity Completed NCT00210808 Phase 2, Phase 3 topiramate
30 Meditation-Based Treatment for Binge Eating Disorder Completed NCT00032760 Phase 2, Phase 3
31 Placebo-Controlled Trial of Bupropion for the Treatment of Binge Eating Disorder Completed NCT00414167 Phase 2, Phase 3 bupropion
32 A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder Completed NCT03107026 Phase 3 dasotraline 4mg;dasotraline 6mg;Placebo
33 Lamotrigine in the Treatment of Binge Eating Disorder Associated With Obesity: A Single-Center, Double-Blind, Placebo-Controlled, Flexible-Dose Study in Outpatients Completed NCT00277641 Phase 3 Lamotrigine;placebo
34 Family Therapy in the Treatment of Adolescent Anorexia Nervosa Completed NCT00610753 Phase 3
35 A Randomized, Double-Bind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study to Assess Efficacy and Safety of Rimonabant 20 mg Versus Placebo on Weight Loss and Frequency of Binge Episodes in Obese Patients With Food Craving Completed NCT00481975 Phase 3 rimonabant (SR141716)
36 Combination Pharmacotherapy With Chantix & Bupropion for Smoking Cessation (ChanBan) Completed NCT00587769 Phase 3 Bupropion SR & Varenicline
37 Bupropion-Enhanced CM for Cocaine Dependence Completed NCT02111798 Phase 2, Phase 3 Bupropion XL;placebo
38 Efficacy and Mechanisms of Naltrexone+Bupropion for Binge Eating Disorder Recruiting NCT03539900 Phase 2, Phase 3 Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combination
39 Cognitive-Behavioral and Pharmacologic Treatment of Binge-Eating Disorder and Obesity Recruiting NCT03946111 Phase 2, Phase 3 Naltrexone and Bupropion
40 Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity Recruiting NCT03926052 Phase 3 Lisdexamfetamine Dimesylate;Placebo
41 Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity Recruiting NCT03924193 Phase 3 Lisdexamfetamine Dimesylate
42 Behavioral and Pharmacologic Treatment of Binge Eating and Obesity Recruiting NCT03045341 Phase 2, Phase 3 NB medication (Naltrexone Bupropion combination)
43 Behavioral and Pharmacologic Treatment of Binge Eating and Obesity Enrolling by invitation NCT03047005 Phase 2, Phase 3 NB medication (Naltrexone Bupropion combination)
44 Behavioral and Pharmacologic Treatment of Binge Eating and Obesity Enrolling by invitation NCT03063606 Phase 2, Phase 3 NB Medication (on-going from acute treatment)
45 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Study to Assess the Efficacy of Topiramate for Weight Loss in Subjects With Metabolic Syndrome Suspended NCT00243984 Phase 3 topiramate
46 N-acetylcysteine in Bulimia Nervosa Terminated NCT01131572 Phase 2, Phase 3 N-acetylcysteine NAC
47 N-acetylcysteine in the Treatment of Bulimia Nervosa Terminated NCT01033149 Phase 3 N-acetylcysteine
48 Liraglutide 3.0mg/d for the Treatment of Binge Eating Disorder Terminated NCT03279731 Phase 3 Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml;Placebo
49 Fluoxetine for the Treatment of Major Depression in Youth With Bipolar Disorder _ Terminated NCT00005015 Phase 3 Fluoxetine
50 An Exploration of the Effects of the Dopamine Agonist Pramipexole on Binge Antecedants, Binge Frequency, and Weight in Binge Eating Disorder Withdrawn NCT01106053 Phase 3 Pramipexole

Search NIH Clinical Center for Bulimia Nervosa

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Fenfluramine
Fenfluramine Hydrochloride
Fluoxetine
Fluoxetine Hydrochloride
Maprotiline
Maprotiline Hydrochloride

Cochrane evidence based reviews: bulimia nervosa

Genetic Tests for Bulimia Nervosa

Genetic tests related to Bulimia Nervosa:

# Genetic test Affiliating Genes
1 Susceptibility to Bulimia Nervosa 29

Anatomical Context for Bulimia Nervosa

MalaCards organs/tissues related to Bulimia Nervosa:

40
Testes, Brain, Cortex, Skin, Prefrontal Cortex, Bone, Ovary

Publications for Bulimia Nervosa

Articles related to Bulimia Nervosa:

(show top 50) (show all 5341)
# Title Authors PMID Year
1
Genetic susceptibility to eating disorders: associated polymorphisms and pharmacogenetic suggestions. 56 61
18855537 2008
2
Linkage analysis of anorexia and bulimia nervosa cohorts using selected behavioral phenotypes as quantitative traits or covariates. 56 61
16152574 2005
3
Significant linkage on chromosome 10p in families with bulimia nervosa. 61 56
12476400 2003
4
Linkage analysis of anorexia nervosa incorporating behavioral covariates. 61 56
11912184 2002
5
Evidence for a susceptibility gene for anorexia nervosa on chromosome 1. 61 56
11799475 2002
6
A preliminary population-based twin study of self-reported eating disorder. 56 61
11232922 2001
7
Controlled family study of anorexia nervosa and bulimia nervosa: evidence of shared liability and transmission of partial syndromes. 56 61
10698815 2000
8
Twin studies of eating disorders: a review. 61 56
10590444 2000
9
A genetic analysis of the eating and attitudes associated with bulimia nervosa: dealing with the problem of ascertainment in twin studies. 61 56
10371753 1999
10
Heritability of binge-eating and broadly defined bulimia nervosa. 61 56
9861464 1998
11
A controlled family study of anorexia nervosa and bulimia nervosa: psychiatric disorders in first-degree relatives and effects of proband comorbidity. 56 61
9672050 1998
12
The genetic epidemiology of bulimia nervosa. 56 61
1842216 1991
13
Correlation of BDNF blood levels with interoceptive awareness and maturity fears in anorexia and bulimia nervosa patients. 54 61
20195875 2010
14
Enhanced ghrelin secretion in the cephalic phase of food ingestion in women with bulimia nervosa. 61 54
19631473 2010
15
The association of catechol-O-methyltransferase genotype with the phenotype of women with eating disorders. 61 54
19852950 2010
16
The possible influence of impulsivity and dietary restraint on associations between serotonin genes and binge eating. 54 61
19493540 2009
17
Functional variants of the serotonin receptor type 3A and B gene are associated with eating disorders. 61 54
19741568 2009
18
Dietary restriction, cardiac autonomic regulation and stress reactivity in bulimic women. 61 54
19497332 2009
19
NGF and BDNF: from nerves to adipose tissue, from neurokines to metabokines. 61 54
20066808 2009
20
Serum visfatin levels in patients with anorexia nervosa and bulimia nervosa. 61 54
19093738 2009
21
Plasma obestatin, ghrelin, and ghrelin/obestatin ratio are increased in underweight patients with anorexia nervosa but not in symptomatic patients with bulimia nervosa. 54 61
18728162 2008
22
Hormonal alteration in obese adolescents with eating disorder: effects of multidisciplinary therapy. 61 54
18547953 2008
23
Meal-induced compositional changes in blood and saliva in persons with bulimia nervosa. 54 61
18175732 2008
24
Clinical features and physiological response to a test meal in purging disorder and bulimia nervosa. 54 61
17768271 2007
25
Alterations in the autonomic control of heart rate variability in patients with anorexia or bulimia nervosa: correlations between sympathovagal activity, clinical features, and leptin levels. 61 54
17598965 2007
26
The 196G/A (val66met) polymorphism of the BDNF gene is significantly associated with binge eating behavior in women with bulimia nervosa or binge eating disorder. 61 54
16901635 2006
27
Gastrointestinal disturbances in eating disorders: clinical and neurobiological aspects. 54 61
16962383 2006
28
Association of catecholamine-O-methyltransferase and 5-HTTLPR genotype with eating disorder-related behavior and attitudes in females with eating disorders. 61 54
16969275 2006
29
Ghrelin concentrations and cardiac vagal tone are decreased after pharmacologic and cognitive-behavioral treatment in patients with bulimia nervosa. 61 54
16643914 2006
30
Investigation of the serotonin transporter regulatory region polymorphism in bulimia nervosa: relationships to harm avoidance, nutritional parameters, and psychiatric comorbidity. 54 61
16449418 2006
31
Association of eating disorders with catechol-o-methyltransferase gene functional polymorphism. 61 54
17028449 2006
32
Serotonin transporter polymorphism and potential response to SSRIs in bulimia nervosa. 61 54
15940301 2005
33
Hormonal and metabolic responses to acute ghrelin administration in patients with bulimia nervosa. 61 54
15808922 2005
34
Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. 61 54
15841111 2005
35
Circulating brain-derived neurotrophic factor is decreased in women with anorexia and bulimia nervosa but not in women with binge-eating disorder: relationships to co-morbid depression, psychopathology and hormonal variables. 54 61
15997610 2005
36
Circulating ghrelin is decreased in non-obese and obese women with binge eating disorder as well as in obese non-binge eating women, but not in patients with bulimia nervosa. 54 61
15511598 2005
37
Investigation of peptide YY and ghrelin responses to a test meal in bulimia nervosa. 61 54
15820714 2005
38
Serum adiponectin and resistin concentrations in patients with restrictive and binge/purge form of anorexia nervosa and bulimia nervosa. 61 54
15598689 2005
39
Altered ghrelin and peptide YY responses to meals in bulimia nervosa. 54 61
15638873 2005
40
Clinical endocrinology and metabolism. Cholecystokinin. 54 61
15533776 2004
41
No changes in serum ghrelin levels in female patients with bulimia nervosa. 61 54
15610931 2004
42
The role of leptin in regulating neuroendocrine function in humans. 54 61
15333744 2004
43
Impaired cholecystokinin secretion and disturbed appetite regulation in women with polycystic ovary syndrome. 61 54
15624269 2004
44
Adiponectin in anorexia nervosa and bulimia nervosa. 54 61
15070952 2004
45
Eating disorders, serotonin transporter polymorphisms and potential treatment response. 54 61
14987118 2004
46
Ghrelin and leptin responses to food ingestion in bulimia nervosa: implications for binge-eating and compensatory behaviours. 54 61
14672247 2003
47
Decreased levels of serum brain-derived neurotrophic factor in female patients with eating disorders. 61 54
12915293 2003
48
Lower serum leptin levels in female students of the nutritional sciences with eating disorders. 54 61
12811471 2003
49
The role of leptin in the etiopathogenesis of anorexia nervosa and bulimia. 61 54
12880190 2003
50
Leptin secretion is related to chronicity and severity of the illness in bulimia nervosa. 61 54
12461192 2002

Variations for Bulimia Nervosa

Expression for Bulimia Nervosa

Search GEO for disease gene expression data for Bulimia Nervosa.

Pathways for Bulimia Nervosa

Pathways related to Bulimia Nervosa according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14 PYY OXT NPY MC4R LEP INS
2
Show member pathways
13.38 PYY OXT NPY MC4R LEP HTR2C
3 12.18 OXT NPY HTR1B GHRL DRD2 BDNF
5 12.04 SLC6A4 MAOA HTR3A HTR2A BDNF
6
Show member pathways
11.84 HTR2C HTR2A HTR1B DRD4 DRD2
7 11.79 SLC6A4 MAOA HTR3A HTR2C HTR2A HTR1B
8 11.63 HTR2C HTR2A DRD2
9 11.08 SLC6A4 MAOA HTR3A HTR2C HTR2A HTR1B
10
Show member pathways
11.05 SLC6A4 MAOA COMT
11
Show member pathways
10.79 SLC6A4 MAOA HTR1B DRD4 DRD2 COMT
12
Show member pathways
10.74 MAOA COMT
13 10.67 MAOA COMT
14 10.53 PYY NPY MC4R LEP INS HTR2C

GO Terms for Bulimia Nervosa

Cellular components related to Bulimia Nervosa according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 10.06 PYY OXT NPY LEP INS GHRL
2 integral component of plasma membrane GO:0005887 10.02 SLC6A4 HTR3A HTR2C HTR2A HTR1B DRD4
3 cell GO:0005623 9.95 OXT NPY HTR2C HTR2A GHRL DRD4
4 synapse GO:0045202 9.91 SLC6A4 NPY HTR3A HTR2C HTR2A DRD2
5 glutamatergic synapse GO:0098978 9.77 HTR3A HTR2A GHRL DRD4 DRD2
6 axon GO:0030424 9.7 HTR3A HTR2A GHRL DRD2 COMT CCK
7 integral component of postsynaptic membrane GO:0099055 9.56 SLC6A4 HTR3A HTR2A DRD2
8 dendrite GO:0030425 9.56 HTR2C HTR2A HTR1B DRD4 DRD2 COMT
9 serotonergic synapse GO:0099154 9.32 SLC6A4 HTR1B
10 integral component of presynaptic membrane GO:0099056 9.02 SLC6A4 HTR3A HTR2A HTR1B DRD2

Biological processes related to Bulimia Nervosa according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 9.97 OXT MC4R LEP INS HTR3A HTR2C
2 cellular calcium ion homeostasis GO:0006874 9.9 HTR2C HTR2A DRD4
3 positive regulation of cold-induced thermogenesis GO:0120162 9.89 OXT LEP GHRL
4 female pregnancy GO:0007565 9.89 OXT LEP COMT
5 response to ethanol GO:0045471 9.89 LEP HTR3A HTR1B DRD2
6 circadian rhythm GO:0007623 9.88 SLC6A4 LEP BDNF
7 chemical synaptic transmission GO:0007268 9.88 NPY HTR3A HTR2C HTR2A HTR1B DRD4
8 response to drug GO:0042493 9.87 SLC6A4 HTR2C HTR2A HTR1B DRD2 COMT
9 excitatory postsynaptic potential GO:0060079 9.85 HTR3A GHRL DRD2
10 positive regulation of synapse assembly GO:0051965 9.85 OXT GHRL BDNF
11 glucose metabolic process GO:0006006 9.85 LEP INS GHRL
12 regulation of synaptic vesicle exocytosis GO:2000300 9.84 HTR2A HTR1B DRD2
13 release of sequestered calcium ion into cytosol GO:0051209 9.83 HTR2C HTR2A DRD2
14 social behavior GO:0035176 9.83 SLC6A4 OXT DRD4
15 response to amphetamine GO:0001975 9.81 OXT DRD4 DRD2
16 regulation of dopamine secretion GO:0014059 9.79 HTR2A HTR1B DRD2
17 regulation of sensory perception of pain GO:0051930 9.79 OXT COMT CCK
18 behavioral fear response GO:0001662 9.78 HTR2C DRD4 BDNF
19 G protein-coupled serotonin receptor signaling pathway GO:0098664 9.77 HTR2A HTR1B DRD4
20 memory GO:0007613 9.77 SLC6A4 OXT HTR2A CCK BDNF
21 response to cocaine GO:0042220 9.76 OXT HTR3A HTR1B DRD2
22 negative regulation of protein secretion GO:0050709 9.75 INS DRD4 DRD2
23 eating behavior GO:0042755 9.74 OXT LEP CCK
24 vasoconstriction GO:0042310 9.73 SLC6A4 HTR1B
25 central nervous system neuron development GO:0021954 9.73 NPY LEP
26 regulation of metabolic process GO:0019222 9.73 MC4R LEP BDNF
27 G protein-coupled receptor signaling pathway GO:0007186 9.73 PYY OXT NPY MC4R INS HTR2C
28 negative regulation of voltage-gated calcium channel activity GO:1901386 9.72 DRD4 DRD2
29 behavioral response to ethanol GO:0048149 9.72 DRD4 DRD2
30 energy reserve metabolic process GO:0006112 9.72 MC4R LEP
31 positive regulation of renal sodium excretion GO:0035815 9.72 OXT DRD2
32 behavioral response to cocaine GO:0048148 9.72 HTR2A DRD4 DRD2
33 grooming behavior GO:0007625 9.71 OXT DRD2
34 G protein-coupled receptor internalization GO:0002031 9.71 HTR1B DRD2
35 sleep GO:0030431 9.71 OXT HTR2A
36 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.71 HTR2A HTR1B DRD2
37 catecholamine metabolic process GO:0006584 9.7 MAOA COMT
38 inhibitory postsynaptic potential GO:0060080 9.7 DRD4 BDNF
39 positive regulation of growth hormone secretion GO:0060124 9.7 GHRL DRD2
40 neurotransmitter catabolic process GO:0042135 9.7 MAOA COMT
41 dopamine metabolic process GO:0042417 9.7 DRD4 DRD2 COMT
42 negative regulation of appetite GO:0032099 9.69 LEP CCK
43 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.69 DRD4 DRD2
44 postsynaptic modulation of chemical synaptic transmission GO:0099170 9.69 GHRL DRD2
45 behavior GO:0007610 9.69 HTR2C HTR2A HTR1B
46 intestinal epithelial cell differentiation GO:0060575 9.68 PYY NPY
47 dopamine catabolic process GO:0042420 9.68 MAOA COMT
48 negative regulation of synaptic transmission, GABAergic GO:0032229 9.67 HTR1B BDNF
49 adult feeding behavior GO:0008343 9.67 NPY LEP GHRL
50 negative regulation of feeding behavior GO:2000252 9.66 MC4R INS

Molecular functions related to Bulimia Nervosa according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.98 NPY MC4R HTR2C HTR2A HTR1B DRD4
2 G protein-coupled receptor binding GO:0001664 9.67 PYY NPY GHRL
3 G protein-coupled serotonin receptor activity GO:0004993 9.67 HTR2C HTR2A HTR1B DRD4
4 neurotransmitter receptor activity GO:0030594 9.65 HTR3A HTR2C HTR2A HTR1B DRD4
5 neuropeptide hormone activity GO:0005184 9.62 PYY OXT NPY CCK
6 drug binding GO:0008144 9.55 HTR2C HTR2A HTR1B DRD4 DRD2
7 dopamine binding GO:0035240 9.52 DRD4 DRD2
8 peptide hormone receptor binding GO:0051428 9.51 LEP CCK
9 hormone activity GO:0005179 9.5 PYY OXT NPY LEP INS GHRL
10 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.48 DRD4 DRD2
11 dopamine neurotransmitter receptor activity GO:0004952 9.46 DRD4 DRD2
12 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding GO:0071886 9.4 HTR2C HTR2A
13 serotonin binding GO:0051378 9.02 SLC6A4 HTR3A HTR2C HTR2A HTR1B

Sources for Bulimia Nervosa

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....